John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis
Conclusions: NAT therapy in JCV-seronegative RRMS patients is safe and results in the absence of PML cases. In Poland, JCV seroconversion rate is similar to that observed in other European countries.Eur Neurol
Source: European Neurology - Category: Neurology Source Type: research
More News: Brain | Clinical Trials | Multiple Sclerosis | Neurology | Poland Health | Study | Tysabri